GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Race Oncology Ltd (ASX:RAC) » Definitions » Price-to-Owner-Earnings

Race Oncology (ASX:RAC) Price-to-Owner-Earnings : (As of Apr. 18, 2025)


View and export this data going back to 2016. Start your Free Trial

What is Race Oncology Price-to-Owner-Earnings?

As of today (2025-04-18), Race Oncology's share price is A$0.925. Race Oncology does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Race Oncology's Price-to-Owner-Earnings or its related term are showing as below:


ASX:RAC's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 31.91
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2025-04-18), Race Oncology's share price is A$0.925. Race Oncology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was A$-0.05. Therefore, Race Oncology's PE Ratio (TTM) for today is At Loss.

As of today (2025-04-18), Race Oncology's share price is A$0.925. Race Oncology's EPS without NRI for the trailing twelve months (TTM) ended in was A$-0.05. Therefore, Race Oncology's PE Ratio without NRI for today is At Loss.


Race Oncology Price-to-Owner-Earnings Historical Data

The historical data trend for Race Oncology's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Race Oncology Price-to-Owner-Earnings Chart

Race Oncology Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only - - - - -

Race Oncology Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Race Oncology's Price-to-Owner-Earnings

For the Biotechnology subindustry, Race Oncology's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Race Oncology's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Race Oncology's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Race Oncology's Price-to-Owner-Earnings falls into.


;
;

Race Oncology Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Race Oncology's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.925/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Race Oncology  (ASX:RAC) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Race Oncology Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Race Oncology's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Race Oncology Business Description

Traded in Other Exchanges
N/A
Address
1 Macquarie Place, Level 36, Gateway, Sydney, NSW, AUS, 2000
Race Oncology Ltd is a clinical stage biopharmaceutical company with a mission to be at the heart of cancer care. Its asset, bisantrene, is a small molecule chemotherapeutic. Bisantrene has a clinical history with demonstrated therapeutic benefits in both adult and pediatric patients, a well-characterized safety profile, and compelling clinical data demonstrating an anticancer effect and less cardiotoxicity over certain anthracyclines, such as doxorubicin. It has reformulated bisantrene (RC220) to address the high unmet needs of patients across multiple oncology indications, with a clinical focus on anthracycline combinations, where Race can deliver cardioprotection and enhanced anticancer activity in solid tumors.

Race Oncology Headlines

No Headlines